Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.41 |
| ▸ | RPTOR | Q8N122 | 14/20 | 0.41 |
| ▸ | MLST8 | Q9BVC4 | 14/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | PDE6A | P16499 | 1/20 | 0.33 |
| ▸ | PDE6B | P35913 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137134 | 0.87 | MTOR (0.52) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522489 | 0.87 | MTOR (0.52) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL137140 | 0.82 | MTOR (0.57) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL29522064 | 0.82 | MTOR (0.57) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL29522292 | 0.76 | MTOR (0.52) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138713 | 0.76 | MTOR (0.52) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138814 | 0.76 | MTOR (0.56) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522273 | 0.76 | MTOR (0.56) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29521572 | 0.76 | MTOR (0.43) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL135891 | 0.76 | MTOR (0.43) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909627-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2825170-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825168-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2817029-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2768500-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2739751-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | Signal Pharmaceuticals, LLC (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014066125-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013138557-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138556-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013126636-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013059396-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |